Ipca Laboratories Ltd

IPCALAB NSE Healthcare Pharmaceuticals
Nifty 500 Midcap 150 LargeMid 250
₹1,968.50
-0.12%
Delayed · cached 15 min
Fair Value Analysis →

Price Chart

Price50-day avg200-day avg

How to read this: the line is the closing price over time. The two dashed lines are moving averages — the average price over the last 50 and 200 trading days — which smooth out daily noise to show the broader trend. Price above its moving averages reflects recent strength; below reflects recent weakness. Use the buttons to change the time range. Prices are end-of-day, not live.

Strengths

  • Low debt: debt-to-equity of 0.1.
  • Comfortable interest cover: operating profit covers interest about 25.2 times.
  • Return on equity is healthy at 15.7%.
  • Return on capital employed is healthy at 17%.
  • Net profit margin is 12.3%.
  • Sales have compounded about 12% a year over five years.
  • Pays a dividend (yield about 0.3%).
  • Has paid a dividend in 4 of the last 5 years.
  • Promoters hold a sizeable stake (44.72%).

!Watch-points

  • Profit growth has been slow over five years (about 1% a year).

These points are generated automatically from the company’s reported figures to highlight what stands out. They are descriptive observations for educational purposes only — not advice or a recommendation to buy, sell, or hold.

Forensic Checks

Altman Z-ScoreSafe zone
4.65

In Altman’s original study, companies in this range showed a low incidence of financial distress.

Computed without the working-capital term (current-asset split not available for this stock).

Piotroski F-ScoreModerate
6 / 7

The F-Score adds one point for each of several year-on-year signs of improving profitability, lower leverage and better efficiency. Higher is generally stronger.

Based on 7 of the 9 signals — the rest need data not available for this stock.

These are well-known academic screening models, shown for educational context only. They describe historical financial patterns and are not predictions, advice, or a recommendation to buy, sell, or hold.

Key Ratios

Market Cap₹ 49,942 Cr
Current Price₹ 1,968.50
High / Low₹ 2,001.50 / 1,251.60
Stock P/E38.171417
Book Value₹ 318.00
Dividend Yield0%
ROCE17.00%
ROE15.70%
Face Value₹ 1.00
Debt to Equity0.10
PEG Ratio0.98
EV / EBITDA21.08
Industry PE35.70
P/B Ratio6.1933093
EPS₹ 44.98
Debt₹ 809 Cr
PAT Margin12.33%
Cash PAT₹ 1,602 Cr
ICR25.19
Promoter Holding44.72%
FII Holding10.72%
DII Holding37.04%
Public Holding7.19%

Note on calculated ratios: where a value is not published in the source data, we compute it from the reported financials — Debt to Equity = total borrowings ÷ (equity capital + reserves); EV / EBITDA = (market cap + debt − cash) ÷ (operating profit + depreciation); PEG = P/E ÷ 3-year profit growth %. These may differ slightly from other sources that use different periods or TTM figures. Current Price, Market Cap and P/E reflect the live quote (cached 15 min).

Compounded Sales Growth
10 Years 13.00%
5 Years 12.00%
3 Years 16.00%
TTM 11.00%
Compounded Profit Growth
10 Years 30.00%
5 Years 1.00%
3 Years 37.00%
TTM 54.00%
Stock Price CAGR
10 Years 21.00%
5 Years 9.00%
3 Years 30.00%
1 Year 50.00%
Return on Equity
10 Years 14.00%
5 Years 13.00%
3 Years 13.00%
Last Year 16.00%
Educational data only. Not a recommendation to buy, sell or hold any security.